The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications

Expert Opinion on Biological Therapy

Volumn 4, Issue 5, 2004, Pages 741-748

  Khan, Safdar N ^a   Lane, Joseph M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Clinical outcomes; Recombinant human bone morphogenetic protein 2; Segmental defects; Spinal fusion; Tibial trauma

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ANIMAL MODEL; BLEEDING; BONE GRAFT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEMINERALIZATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FRACTURE HEALING; HEALTH CARE COST; HUMAN; ILIAC CREST; INTRAMEDULLARY NAILING; LAPAROSCOPIC SURGERY; OPERATION DURATION; ORTHOPEDIC SURGERY; OUTCOMES RESEARCH; PATIENT SATISFACTION; PILOT STUDY; REVIEW; SPINE FUSION; TIBIA FRACTURE; TREATMENT INDICATION;

BONE DEVELOPMENT; BONE MORPHOGENETIC PROTEINS; CLINICAL TRIALS; FRACTURES, BONE; HUMANS; ORTHOPEDIC PROCEDURES; RECOMBINANT PROTEINS; SPINAL FUSION; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 2442638878     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.5.741     Document Type: Review

References (27)

1. URIST MR: Bone: formation by autoinduction. Science (1965) 150:893-899. Classic article containing pioneering work regarding the osteoinductivity of bone matrix proteins.
2. URIST MR, MIKULSKI A, LIETZE A: Solubilized and insolubilized bone morphogenetic protein. Proc. Natl. Acad. Sci. USA (1979) 76:1828-1832.
3. URIST MR, SILVERMAN BF, BURING K, DUBUC FL, ROSENBERG JM: The bone induction principle. Clin. Orthop. (1967) 53:243-283.
4. WANG EA, ROSEN V, CORDES P et al.: Purification and characterization of other distinct bone-inducing factors. Proc. Natl. Acad. Sci. USA (1988) 85(24):9484-9488.
5. MCKAY B, SANDHU HS: Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine (2002) 27(16 Suppl. 1):S66-S85. Excellent review covering all IDE clinical trials for spinal fusion prior to FDA approval.
6. MATSUO T, SUGITA T, KUBO T, YASUNAGA Y, OCHI M, MURAKAMI T: Injectable magnetic liposomes as a novel carrier of recombinant human BMP-2 for bone formation in a rat bone-defect model. J. Biomed. Mater. Res. (2003) 66A(4):747-754.
7. KOKUBO S, FUJIMOTO R, YOKOTA S et al.: Bone regeneration by recombinant human bone morphogenetic protein-2 and a novel biodegradable carrier in a rabbit ulnar defect model. Biomaterials (2003) 24(9):1643-1651.
8. MURAKAMI N, SAITO N, HORIUCHI H, OKADA T, NOZAKI K, TAKAOKA K: Repair of segmental defects in rabbit humeri with titanium fiber mesh cylinders containing recombinant human bone morphogenetic protein-2 (rhBMP-2) and a synthetic polymer. J. Biomed. Mater. Res. (2002) 62(2):169-174.
9. SCIADINI MF, JOHNSON KD: Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J. Orthop. Res. (2000) 18(2):289-302.
10. GERHART TN, KIRKER-HEAD CA, KRIZ MJ et al.: Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin. Orthop. (1993) (293):317-326.
11. SANDHU HS, KABO JM, TURNER AS, LUI D, KANIM LEA, TOTH JM: rhBMP-2 augmentation of titanium fusion cages for experimental anterior lumbar fusion. Annual Meeting of the North American Spine Society. New York, NY, USA (22-25 October, 1996).
12. SANDHU HS, TOTH JM, DIWAN AD et al.: Histologic evaluation of the efficacy of rhBMP-2 compared with autograft bone in sheep spinal anterior interbody fusion. Spine (2002) 27:567-575.
13. ZDEBLICK TA, HEIM SE, KLEEMAN TJ et al.: Laparoscopic approach with tapered metal cages: rhBMP-2 versus autograft. Annual Meeting of the North American Spine Society. Seattle, WA, USA (31 Oct-3 Nov 2001).
14. BODEN S, MARTIN G, HORTON WC, TRUSST, SANDHU H: Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. J. Spinal Disord. (1998) 11(2):95-101.
15. SANDHU HS, KANIM LEA, KABO JM et al.: Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine (1996) 21(18):2115-2122.
16. SANDHU HS, KANIM LEA, TOTH JM et al.: Experimental spinal fusion with recombinant bone morphogenetic protein-2 without decortication of osseous elements. Spine (1997) 22(11):1171-1180.
17. FISCHGRUND JS, JAMES SB, CHABOT MC et al.: Augmentation of autograft using rhBMP-2 and different carrier media in the canine spinal fusion model. J. Spinal Disord. (1997) 10(6):467-472.
18. MARTIN GJ, BODEN SD, MORONE MA, MOSKOVITZ PA: Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a non-human primate: Important lessons learned regarding dose, carrier, and safety. J. Spinal Disord. (1999) 12(3):179-186. One of the most important feasibility and efficacy studies to date. Data from this study led to carrier and dose modifications that were used in subsequent pilot and pivotal clinical trials.
19. BODEN S, MARTIN G, MORONE MA, UGBO J, MOSKOVIZ P: Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein-2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine (1999) 24(12):1179-1185.
20. SUH DY, BODEN SD, LOUIS-UGBO J et al.: Delivery of recombinant human bone morphogenetic protein-2 using a compression resistant matrix in posterolateral spine fusion in the rabbit and the non-human primate. Spine (2002) 27:353-360.
21. SUH DY, BODEN SD, UGBO JL: Use of rhBMP-2 supplemented with allograft bone chips in posterolateral fusions in nonhuman primates. Annual Meeting of the American Academy of Orthopedic Surgeons. Dallas, TX, USA (13-17 February 2002).
22. MINAMIDE A, AKAMARU A, UGBO JL, BODEN SD: Use of rhBMP-2 supplemented with allograft bone chips in posterolateral fusions in nonhuman primates. Annual Meeting of the North American Spine Society. Seattle, WA, USA (31 October-3 November 2001).
23. JOHNSON EE, URIST MR, FINERMAN GA: Bone morphogenetic protein augmentation grafting of resistant femoral nonunions. A preliminary report. Clin. Orthop. (1988) (230):257-265.
24. JOHNSON EE, URIST MR, FINERMAN GA: Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein. A preliminary report. Clin. Orthop. (1988) (236):249-257.
25. BODEN SD, ZDEBLICK TA, SANDHU HS, HEIM SE: The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine (2000) 25(3):376-381. First ever report indicating the absolute clinical evidence of osteoinductivity in patients undergoing ALIE
26. GOVENDER S, CSIMMA C, GENANT HK et al.: Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. J. Bone Joint Surg. Am. (2002) 84-A(12):2123-2134.
27. BODEN SD, KANG J, SANDHU H, HELLER JG: Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (2002) 27(23):2662-2673.